Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
JW Therapeutics Raises USD90 Million in Series A Financing 15
AbViro Raises USD0.4 Million in Venture Financing 16
Juno Therapeutics Raises USD134 Million in Series B Financing 17
Juno Therapeutics Raises US$31 Million In Extended Series A Financing 18
Juno Therapeutics Raises US$145 Million In Series A Financing 19
AbVitro Raises US$0.75 Million In Venture Financing 21
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 22
X-BODY Raises Additional US$0.6 Million In Venture Financing 23
Partnerships 24
Seattle Children’s Hospital to Enter into Agreement with Juno Therapeutics 24
Juno Therapeutics Forms Joint Venture with WuXi AppTec 25
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 26
Celgene Exercises Option Agreement with Juno Therapeutics 27
Juno Therapeutics Enters into Research Agreement with Editas Medicine 28
MedImmune Enters into Agreement with Juno Therapeutics 29
Juno Therapeutics Enters into Research Agreement with FHCRC 30
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 31
Licensing Agreements 32
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 32
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 33
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 34
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 35
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 36
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 37
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 38
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 40
Vernalis Enters into Licensing Agreement with RedoxTherapies 41
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children’s Research Hospital 42
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 43
Juno Therapeutics Enters into Licensing Agreement with FHCRC 44
Juno Therapeutics Enters into Licensing Agreement with Trianni 45
Celgene Enters into Licensing Agreement with Juno Therapeutics 46
Equity Offering 47
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 47
Juno Therapeutics Raises USD304 Million in IPO 49
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 51
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 52
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 53
Asset Transactions 54
Roche Acquires PETE Technology from AbVitro 54
Acquisition 55
Celgene Acquires Juno Therapeutics for USD9 Billion 55
Juno Therapeutics Acquires RedoxTherapies 57
Juno Therapeutics Acquires AbVitro 58
Juno Therapeutics Acquires X-BODY 59
AstraZeneca May Acquire Juno Therapeutics 60
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 61
Juno Therapeutics Acquires ZetaRx BioSciences 62
Juno Therapeutics Inc – Key Competitors 63
Juno Therapeutics Inc – Key Employees 64
Juno Therapeutics Inc – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Joint Venture 65
Recent Developments 66
Strategy And Business Planning 66
Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center 66
Financial Announcements 67
Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results 67
Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results 70
May 04, 2017: Juno Therapeutics Reports First Quarter 2017 Financial Results 72
Mar 01, 2017: Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results 74
Corporate Communications 78
Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer 78
Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO 79
May 23, 2017: Juno Therapeutics Appoints Jay Flatley to Board of Directors 80
Apr 19, 2017: Juno Therapeutics Appoints Rupert Vessey to Board of Directors 81
Apr 17, 2017: Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development 82
Jan 27, 2017: Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations 83
Legal and Regulatory 84
Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. – JUNO 84
Government and Public Interest 85
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 85
Product News 86
12/12/2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH 86
12/09/2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL 88
11/01/2017: Juno Therapeutics to Highlight New Advances of Anti-Neoplastic Drug Candidate JCARH125 at ASH Conference 89
Oct 11, 2017: New insights into CAR T-cell therapy’s potential side effects 91
06/05/2017: Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma 93
Clinical Trials 95
Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma 95
Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference 97
Jun 17, 2017: Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma 99
May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting 101
May 09, 2017: First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
JW Therapeutics Raises USD90 Million in Series A Financing 15
AbViro Raises USD0.4 Million in Venture Financing 16
Juno Therapeutics Raises USD134 Million in Series B Financing 17
Juno Therapeutics Raises US$31 Million In Extended Series A Financing 18
Juno Therapeutics Raises US$145 Million In Series A Financing 19
AbVitro Raises US$0.75 Million In Venture Financing 21
AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 22
X-BODY Raises Additional US$0.6 Million In Venture Financing 23
Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 24
Juno Therapeutics Forms Joint Venture with WuXi AppTec 25
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 26
Celgene Exercises Option Agreement with Juno Therapeutics 27
Juno Therapeutics Enters into Research Agreement with Editas Medicine 28
MedImmune Enters into Agreement with Juno Therapeutics 29
Juno Therapeutics Enters into Research Agreement with FHCRC 30
X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 31
Juno Therapeutics Enters into Licensing Agreement with Thermo Fisher Scientific 32
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 33
Juno Therapeutics Enters into Licensing Agreement with Oncotracker 34
Juno Therapeutics Enters into Licensing Agreement with Fred Hutchinson Cancer 35
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 36
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 37
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 38
Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 40
Vernalis Enters into Licensing Agreement with RedoxTherapies 41
Juno Therapeutics Enters into Licensing Agreement with St. Jude Children’s Research Hospital 42
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 43
Juno Therapeutics Enters into Licensing Agreement with FHCRC 44
Juno Therapeutics Enters into Licensing Agreement with Trianni 45
Celgene Enters into Licensing Agreement with Juno Therapeutics 46
Juno Therapeutics Raises USD287.6 Million in Public Offering of Shares 47
Juno Therapeutics Raises USD304 Million in IPO 49
Juno Therapeutics Raises USD133.7 Million in Private Placement of Series B Preferred Shares 51
Juno Therapeutics Raises USD31.31 Million in Private Placement of Series A-2 Preferred Shares 52
Juno Therapeutics Raises USD31.3 Million in Private Placement of Series A-2 Preferred Shares 53
Roche Acquires PETE Technology from AbVitro 54
Celgene Acquires Juno Therapeutics for USD9 Billion 55
Juno Therapeutics Acquires RedoxTherapies 57
Juno Therapeutics Acquires AbVitro 58
Juno Therapeutics Acquires X-BODY 59
AstraZeneca May Acquire Juno Therapeutics 60
Juno Therapeutics Acquires Remaining 95.24% Stake in Stage Cell Therapeutics 61
Juno Therapeutics Acquires ZetaRx BioSciences 62
Juno Therapeutics Inc, Key Competitors 63
Juno Therapeutics Inc, Key Employees 64
Juno Therapeutics Inc, Subsidiaries 65
Juno Therapeutics Inc, Joint Venture 65
List of Figures
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11